Show simple item record

dc.contributor.authorPascual-Figal, Domingo A 
dc.contributor.authorBayes-Genis, Antoni
dc.contributor.authorAsensio-Lopez, Maria Carmen
dc.contributor.authorHernández-Vicente, Alvaro
dc.contributor.authorGarrido-Bravo, Iris
dc.contributor.authorPastor-Perez, Francisco
dc.contributor.authorDíez, Javier
dc.contributor.authorIbanez, Borja 
dc.contributor.authorLax, Antonio
dc.identifier.citationJ Am Coll Cardiol. 2019; 73(9):1016-1025es_ES
dc.description.abstractBACKGROUND: Soluble ST2 (sST2), which is the soluble form of interleukin (IL)-1 receptor-like 1, identifies risk in acutely decompensated heart failure (ADHF). IL-1β is an inflammatory cytokine that has deleterious effects in myocardial remodeling and function. IL-1β inhibition has beneficial effects after acute myocardial infarction. However, the role of IL-1β in ADHF and its relationship to ST2 remain unclear. OBJECTIVES: This study sought to investigate the relationship between IL-1β and sST2, and the prognostic impact of such a relationship in patients with ADHF. METHODS: This study examined 316 consecutive patients who were hospitalized with ADHF (72 ± 12 years of age, 57% male, and left ventricular ejection fraction 45 ± 17%). Blood samples were collected at presentation, and IL-1β and sST2 levels were measured. All-cause mortality was obtained for all patients at 1 year. RESULTS: The IL-1β concentration at presentation was associated with prior HF hospitalizations, functional impairment, and higher N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T concentrations. IL-1β was higher in patients who died during the year after hospitalization (n = 52, 16.5%) (p = 0.005), and the optimal threshold was identified with levels over 49.1 pg/ml (hazard ratio: 2.5; 95% confidence interval: 1.43 to 4.49; p = 0.0014). Circulating IL-1β positively correlated with sST2 (ρ = 0.65; p < 0.001). Considering the prognostic thresholds of IL-1β (≥49.1 pg/ml) and sST2 (≥35.0 ng/ml) concentrations: all patients with low sST2 also presented with low IL-1β; among patients with high sST2, only those with also high IL-1β had a significantly higher risk of death (30% vs. 14%; hazard ratio: 2.52; 95% confidence interval: 1.40 to 4.56; p = 0.002). CONCLUSIONS: Circulating IL-1β concentrations are clinically meaningful in ADHF patients and interplay with the predictive ability of sST2. IL-1 axis-related inflammation signaling may represent a therapeutic target in ADHF.es_ES
dc.description.sponsorshipThis work has been supported by grants PI14/01637 and PI17/01742 from "Instituto de Salud Carlos III," Madrid, Spain, and grant PI14/19334 from "Fundacion Seneca de Ciencia y Tecnologia de la Region de Murcia," Murcia, Spain. Dr. Pascual-Figal has received grant support from Roche Diagnostics; and has received educational fees from Novartis. Dr. Bayes-Genis has received speaker fees from Novartis, Roche, and Critical Diagnostics. Dr. Diez has received educational fees from Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.es_ES
dc.subjectheart failurees_ES
dc.subject.meshAcute Disease es_ES
dc.subject.meshAged es_ES
dc.subject.meshBiomarkers es_ES
dc.subject.meshCause of Death es_ES
dc.subject.meshEnzyme-Linked Immunosorbent Assay es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHeart Failure es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInterleukin-1 es_ES
dc.subject.meshMale es_ES
dc.subject.meshPrognosis es_ES
dc.subject.meshProspective Studies es_ES
dc.subject.meshROC Curve es_ES
dc.subject.meshRisk Assessment es_ES
dc.subject.meshRisk Factors es_ES
dc.subject.meshSpain es_ES
dc.subject.meshStroke Volume es_ES
dc.subject.meshSurvival Rate es_ES
dc.subject.meshVentricular Function, Left es_ES
dc.subject.meshRegistries es_ES
dc.titleThe Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failurees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.contributor.funderRegión de Murciaes_ES
dc.contributor.funderRoche Diagnosticses_ES
dc.contributor.funderNovartis Farmaceutica S.A.es_ES
dc.identifier.journalJournal of the American College of Cardiologyes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional